Steffen Lang

President, Operations · Novartis

Pharmaceuticals

Steffen Lang is Novartis’s president of Operations. His career has moved from research and pharmaceutical development into biologics manufacturing and leadership of the company’s technical operations.

Last reviewed: Nov 15, 2026

Executive Summary

Steffen Lang is Novartis’s president of Operations. His career has moved from research and pharmaceutical development into biologics manufacturing and leadership of the company’s technical operations.

Career Highlights

  • Became president of the expanded Operations unit in April 2022.
  • Led Novartis Technical Operations from 2017 to 2022.
  • Joined the company in research in 1994.

Professional Journey

Lang completed pharmaceutical-sciences study at Heidelberg and a doctorate in pharmaceutical technology at the Swiss Federal Institute of Technology. He joined Novartis in 1994 as a research laboratory head and later moved through pharmaceutical-development leadership roles.

From 2009 to 2015 he was global head of Technical Research and Development for Pharmaceuticals. He then led Biologics Technical Development and Manufacturing within Novartis Technical Operations.

He became global head of Technical Operations in 2017. His work included adapting manufacturing capabilities to the company’s changing medicines portfolio and supporting advanced therapeutic platforms. The organization also collaborated with industry partners supplying COVID-19 vaccines and therapies.

Lang became president of Operations when Novartis combined Technical Operations and its corporate-services organization in April 2022. His portfolio now brings manufacturing, quality and supply together with information technology, data and digital, procurement, environmental sustainability, facilities and global business services.

Education

Doctorate — Swiss Federal Institute of Technology — Pharmaceutical Technology.

Master’s degree — University of Heidelberg — Pharmaceutical Sciences.